State Street’s Anbio Biotechnology NNNN Stock Holding History

State Street’s Portfolio NNNN Stock Details NNNN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$161K	Buy	+25,608	New	+$218K	﹤0.01%	3963

Other funds holding NNNN

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

SPL

Superior Planning, LLC San Diego, California $240M AUM

Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return

Ameritas Advisory Services Lincoln, Nebraska $5.22B AUM 19.55% 1-Year Est. Return

Larson Financial Group St Louis, Missouri $4.11B AUM 23.62% 1-Year Est. Return

EverSource Wealth Advisors Birmingham, Alabama $3.11B AUM 21.48% 1-Year Est. Return

Pinnacle Wealth Planning Services Mansfield, Ohio $1.03B AUM 22.32% 1-Year Est. Return

State Street's NNNN Position: Q3 2026 in Review

State Street opened a new position in Anbio Biotechnology (NNNN) in Q3 2026: 25,608 shares worth $161K. The stake represents ﹤0.01% of the portfolio and ranks #3963 among its holdings.

11 funds tracked by Wall St. Rank hold NNNN as of Q3 2026.

State Street held 25,608 shares of Anbio Biotechnology worth $161K as of Q3 2026.
Anbio Biotechnology was a new State Street position in Q3 2026.
Anbio Biotechnology made up ﹤0.01% of State Street's portfolio in Q3 2026, its #3963 holding.
11 funds tracked by Wall St. Rank held Anbio Biotechnology as of Q3 2026.

Based on State Street's 13F filing for Q3 2026, filed 12 Nov 2026.